Sarcoma targeted drugs

Share This Post

Targeted therapy for sarcoma treatment

No stranger to cancer, not much information about sarcoma. In fact, sarcoma is a type of cancer that is often ignored by people. This kind of cancer appears in the skin and periosteum, and it is quite equivalent to find that the condition worsens Quickly, the emergence of sarcoma-targeting drugs can allow patients to breathe, can stabilize the disease in a short course of time, and then prevent the serious situation of metastasis, reducing the risk of life-threatening to patients.

Targeted drug for sarcoma

Bevacizumab, pazopanib, sunitinib, etc. are sarcoma-targeting drugs, but this is not suitable for every patient. The prerequisite is to do genetic testing. If the gene mutation is a KRAS mutation, MEK inhibitors can be used, if it is a PIK3CA mutation, BKM120, mTOR inhibitor, etc. If it is an EGFR mutation, a TIKi drug can be used. Targeted drugs still have ideas, but the key is to know exactly what a genetic mutation is, which requires the help of second-generation sequencing technology because the frequency of genetic mutations in KRAS, PIK3CA, EGFR and MET does not add up to 100%. If conditions permit, AVASTIN can also be used in combination with chemotherapy.

What are sarcoma-targeting drugs?


Bevacizumab, a human recombinant VEGF antibody, has been shown to have clinical efficacy in combination regimens in rectal cancer and other malignancies. Agulnik et al. Conducted a multi-center prospective, phase II clinical trial to evaluate the safety and effectiveness of the single-agent bevacizumab, including 30 patients with advanced STS, including 23 cases of angiosarcoma and 7 cases of epithelioid hemangioendothelioma. Monotherapy was well tolerated, partial response (PR), 2 cases, stable disease (SD), 15 cases. After two cycles of treatment, the median progression-free survival (PFS) was 12 weeks, and the overall survival (OS) was 52.7 weeks. This test shows that bevacizumab is safe and effective in patients with angiosarcoma and epithelioid hemangioendothelioma.


Pazopanib is an oral multi-targeted small molecule receptor tyrosine kinase inhibitor, and is the first targeted drug approved by the FDA for decades to treat advanced soft tissue sarcoma (non-liposarcoma). Pazopanib is a vascular endothelial growth factor receptor VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α and -β, FGFR-1 and -3, cytokine receptor (Kit), interleukin-2 receptor A receptor tyrosine kinase inhibitor that can induce T cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). FDA approves pazopanib for patients with advanced sarcoma.


Sunitinib is an oral small molecule receptor tyrosine kinase inhibitor with multiple effects of inhibiting tumor angiogenesis and anti-tumor cell growth. Targets for the drug to exert anti-cancer effects include: PDGFR-α and -β, VEGFR1, VEGFR2, VEGFR3, FLT-3, CSF-1R, kit and ret. Sunitide has multiple effector pathways, making it a reliable anti-tumor targeted drug for non-GIST sarcomas, with two phase II clinical trials evaluating its safety and effectiveness.


Sorafenib is an oral multikinase inhibitor. It can simultaneously inhibit a variety of intracellular and cell surface kinases, including BRAF kinase, VEGFR-2, VEGFR-3, PDGFR-β, KIT, and FMS-like tyrosine kinase 3 (FLT-3).


Sildenib, a pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, Kummar et al. Found through a phase II clinical study that it showed good efficacy for metastatic acinar soft tissue sarcoma, 35% Patients achieved PR, SD occurred in 60% of patients, and overall disease control rate reached 84% at 24 weeks.

6. Anlotinib

Anlotinib is a multi-target receptor tyrosine kinase (RTK) inhibitor that targets vascular endothelial growth factor receptor (VEGFR1 / 2/3) and fibroblast growth factor receptor (FGFR1 / 2 / 3) Targets such as platelet-derived growth factor receptors (PDGFRα / β), c-Kit, and Ret. In recent years, research into its use in tumor-targeted therapies has continued.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy